pharma · Hepatitis B, Chronic · Cancer
EmeraMed
Immunocore Ireland Limited
Immunocore Ireland is a pharma organization headquartered in GB. Primary therapeutic focus areas include Hepatitis B, Chronic, Cancer, Chronic HIV infection, Advanced PRAME Positive Cancers, Previously untreated advanced
Company details
- Status
- Public
- HQ
- Ranelagh, IE
- Founded
- 2007
- Employees
- 7
- Programs
- 5
- Drugs
- 9
- Patents
- 0
Quick answer
Immunocore Ireland is a pharma organization headquartered in GB. Primary therapeutic focus areas include Hepatitis B, Chronic, Cancer, Chronic HIV infection, Advanced PRAME Positive Cancers, Previously untreated advanced uveal melanoma (UM). NovaPharmaNews links 5 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (3), phase 1 (2).
Company snapshot
EmeraMed Limited acquired CTI Science, Inc. in July 2014. The Company was founded by Dr. Boyd E. Haley, PhD, former Chair of the Department of Chemistry at the University of Kentucky and is developing a flagship product for submission for regulatory drug approval. Please visit the Company's website www.EmeraMed.com for more information.
- 5 active pipeline program(s) linked via ClinicalTrials.gov.
- 5 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for EmeraMed. Not investment advice.
Top assets
Lead pipeline drugs
- Marketed / approved
- approved
- approved
- Marketed / approved
Active clinical programs
- Phase 2
- Phase 2
- Phase 2
- Phase 1
Momentum
Proprietary activity score for EmeraMed.
1 active signal
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for EmeraMed.
- Clinical update
- Clinical update
Phase 1 Study of IMC-P115C in Advanced PRAME Positive Cancers — Phase 1
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is EmeraMed?
-
Is EmeraMed publicly traded?
-
What drugs does EmeraMed develop or market?
-
What are the latest developments for EmeraMed?
-
What therapeutic areas does EmeraMed focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.